New research reveals that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional lifestyle regimens.
Published data in a major medical journal points out that while obese individuals can lose about a fifth of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users buying these drugs need to be cognizant of the danger of rapid weight regain when the treatment ends," warns researcher Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment mass in about 18 months.
Analyzing Treatments
The study, which looked at 37 of studies involving over 9,000 of patients, compared the effects of these new drugs with other pills.
Researchers emphasize that individuals who lose weight through lifestyle changes alone usually have a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Experts propose the way of the jabs explains the amplified weight return.
These medications mimic a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing the hormone levels several times higher than normal may cause the body to produce less of its own natural hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Issue?
The NHS suggest the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts argue that, considering the high risk of weight regain, the treatment should be considered long-term.
This perspective is supported by drug manufacturers, who note that the results "underscore the persistent character of excess weight," comparing it to managing diseases like high blood pressure.
User Testimonies
Individuals who have discontinued the medication describe a intense resurgence of appetite.
"I experienced a trigger flipping and you become starving," said a patient.
This challenge is compounded if individuals have not developed sustainable dietary or behavioural modifications during treatment.
Significant Use
Recent estimates suggest that millions of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is higher among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while these medications are effective tools for shedding pounds, they are not a permanent solution and long-term success hinges on ongoing lifestyle changes.
